Comparison Between Total Intravenous Anesthesia With Magnesium Sulphate Versus Total Intravenous Anesthesia With Dexmedetomidine in Patients Undergoing Lumbar Spine Surgeries

NCT07443163 | Not Yet Recruiting Phase 3

• 1 other identifier: MD-313-2025
• Study Type: interventional
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

Although total intravenous anesthesia (TIVA) provides advantages such as accelerated recuperation and diminished postoperative nausea, it also has constraints, such as the potential for hemodynamic instability and inadequate analgesia. TIVA is less suitable for major surgeries, particularly those involving the spine, when used alone, due to these limitations, as they necessitate substantial muscle relaxation and pain management. A non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, magnesium sulfate (MgSO4), exhibits antinociceptive properties. The infusion of Magnesium during general anesthesia has been shown to decrease the need for anesthesia and the consumption of postoperative analgesics in numerous clinical studies. MgSO4, when utilized as an adjunct to TIVA, has been demonstrated to decrease the duration of extubation, facilitate earlier emergence from anesthesia, and facilitate intraoperative neurophysiological monitoring (IOM) during spine surgery. Dexmedetomidine is a selective α2-adrenoreceptor agonist whose sedative effects are predominantly mediated by its action on α-2 adrenergic receptors in the brain and spinal cord. It delivers efficient sedation without the pronounced respiratory depression that is frequently observed with other sedatives. Dexmedetomidine induces a profound sense of tranquility and alleviates anxiety by selectively targeting specific receptors in the central nervous system, in addition to offering analgesic advantages. Dexmedetomidine has been employed in the surgical intensive care unit to expedite the extubation process. Dexmedetomidine is now being utilized more frequently as an adjuvant for propofol-based TIVA in procedures that necessitateintraoperative neurophysiological monitoring. There is a paucity of literature comparing TIVA with magnesium sulphate and TIVA with dexmedetomidine in spine surgeries.

Conditions

Emergence From Anesthesia

Outcome Measures

Primary Outcomes (1)

• Extubation time

  Time from stoppage of TIVA infusion till extubation of the endotracheal tube

  Up to 2 hours after surgery

Secondary Outcomes (5)

• Time to the first request for the rescue analgesia

  Up to 24 hours after surgery

• Total morphine consumption

  24 hours postoperative

• Ramsay Sedation score

  24 hours postoperative

• Degree of patient satisfaction

  24 hours postoperative

• Incidence of adverse events

  24 hours postoperative

Study Arms (2)

Group D

ACTIVE COMPARATOR

Drug: Dexmedetomidine (Precedex®)

Group M

ACTIVE COMPARATOR

Drug: magnesium sulfate

Interventions

Dexmedetomidine (Precedex®) DRUG

Patients will receive a dexmedetomidine loading dose of 1 µg/kg before induction over a period of 15 min and maintenance of 0.5 µg/kg/h throughout the surgery

Group D

magnesium sulfate DRUG

Patients will receive a magnesium sulfate loading dose of 50 mg/kg before induction over a period of 15 min and maintenance at 15 mg/kg/h throughout the surgery

Group M

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• American Society of Anesthesiologists (ASA) physical status I, II.
• Scheduled for elective spine surgery up to two levels under general anesthesia

You may not qualify if:

• History of preoperative neuromuscular disease, hepatic impairment \[defined as a known diagnosis of liver cirrhosis, hepatitis with elevated liver enzymes (\>2 times upper standard limit), or Child-Pugh score B or C\], renal impairment \[defined as chronic kidney disease with an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m² or history of dialysis\], endocrinal disorders \[including uncontrolled diabetes mellitus (HbA1c \>8.5%), thyroid dysfunction (untreated hypo/hyperthyroidism), or adrenal insufficiency\], hematological disorder \[such as anemia (Hb \<10 g/dL), coagulopathies (INR \>1.5, platelet count \<100,000/mm³), or bleeding diathesis\] or cardiovascular dysfunction \[defined as history of ischemic heart disease, arrhythmias requiring treatment, heart failure (NYHA class II or higher), or uncontrolled hypertension (SBP \>160 mmHg or DBP \>100 mmHg)\].
• Any degree of heart block.
• Known allergy to the study drugs.
• Scoliosis surgery.
• Cervical spine surgeries.
• Surgeries with an anticipated duration of more than 4 hours.
• Receiving magnesium supplementation.
• Any Preoperative Disturbed consciousness level or cognitive dysfunction.
• Drugs known to have a significant interaction with NMDAs.
• Chronic use of opioids and current treatment with a β-blocker or calcium channel blocker.

Sponsors & Collaborators

• Cairo University: lead

MeSH Terms

Interventions

Dexmedetomidine; Magnesium Sulfate

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Magnesium Compounds; Inorganic Chemicals; Sulfates; Sulfuric Acids; Sulfur Acids; Sulfur Compounds

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: lecturer of anaesthesia

Study Record Dates

• First Submitted: February 23, 2026
• First Posted: March 2, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: March 2, 2026

Record last verified: 2026-02